Vion Pharmaceuticals Inc - Current report filing (8-K)
February 20 2008 - 4:36PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported)
February 20, 2008
VION PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
|
|
|
|
000-26534
(Commission File Number)
|
|
13-3671221
(IRS Employer Identification No.)
|
|
|
|
|
4 Science Park, New Haven, CT
(Address of Principal Executive Offices)
|
|
06511
(Zip Code)
|
Registrant’s telephone number, including area code:
(203) 498-4210
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
o
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
o
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
o
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
o
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01
O
ther Events.
On February 20, 2008, Vion Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the Company would implement a one-for-ten reverse stock split of the Company’s issued and outstanding common stock effective at 5:00 pm Eastern time on Wednesday, February 20, 2008. A copy of that press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. A copy of the Certificate of Amendment to the Company’s Restated Certificate of Incorporation effecting the reverse split and a corresponding reduction in the number of shares that the Company is authorized to issue, filed with the Secretary of State of the State of Delaware on February 20, 2008, is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
99.1
|
|
Press release dated February 20, 2008.
|
|
|
|
|
|
99.2
|
|
Amendment to Restated Certificate of Incorporation of Vion Pharmaceuticals, Inc., dated February 20, 2008.
|
|
|
|
|
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
VION PHARMACEUTICALS, INC.
|
|
|
|
|
|
Date: February 20, 2008
|
|
By:
|
/s/ Howard B. Johnson
|
|
|
|
Name:
|
Howard B. Johnson
|
|
|
|
Title:
|
President and Chief Financial Officer
|
-3-
EXHIBIT INDEX
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
99.1
|
|
Press release dated February 20, 2008.
|
|
|
|
|
|
99.2
|
|
Amendment to Restated Certificate of Incorporation of Vion Pharmaceuticals, Inc., dated February 20, 2008.
|
|
|
|
|
-4-
Vion Pharmaceuticals Inc. (MM) (NASDAQ:VIOND)
Historical Stock Chart
From Apr 2024 to May 2024
Vion Pharmaceuticals Inc. (MM) (NASDAQ:VIOND)
Historical Stock Chart
From May 2023 to May 2024
